200 related articles for article (PubMed ID: 23448878)
21. Fcγ receptors III and IV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid.
Schulze FS; Beckmann T; Nimmerjahn F; Ishiko A; Collin M; Köhl J; Goletz S; Zillikens D; Ludwig R; Schmidt E
Am J Pathol; 2014 Aug; 184(8):2185-96. PubMed ID: 25043618
[TBL] [Abstract][Full Text] [Related]
22. Recombinant human IgA1 and IgA2 autoantibodies to type VII collagen induce subepidermal blistering ex vivo.
Recke A; Trog LM; Pas HH; Vorobyev A; Abadpour A; Jonkman MF; van Zandbergen G; Kauderer C; Zillikens D; Vidarsson G; Ludwig RJ
J Immunol; 2014 Aug; 193(4):1600-8. PubMed ID: 25024393
[TBL] [Abstract][Full Text] [Related]
23. A patient with both bullous pemphigoid and epidermolysis bullosa acquisita: an example of intermolecular epitope spreading.
Fairley JA; Woodley DT; Chen M; Giudice GJ; Lin MS
J Am Acad Dermatol; 2004 Jul; 51(1):118-22. PubMed ID: 15243536
[TBL] [Abstract][Full Text] [Related]
24. Bullous pemphigoid autoantibodies directly induce blister formation without complement activation.
Ujiie H; Sasaoka T; Izumi K; Nishie W; Shinkuma S; Natsuga K; Nakamura H; Shibaki A; Shimizu H
J Immunol; 2014 Nov; 193(9):4415-28. PubMed ID: 25261486
[TBL] [Abstract][Full Text] [Related]
25. Passive transfer of autoantibodies from a patient with mutilating epidermolysis bullosa acquisita induces specific alterations in the skin of neonatal mice.
Borradori L; Caldwell JB; Briggaman RA; Burr CE; Gammon WR; James WD; Yancey KB
Arch Dermatol; 1995 May; 131(5):590-5. PubMed ID: 7741548
[TBL] [Abstract][Full Text] [Related]
26. What's new in bullous pemphigoid.
Ujiie H; Shibaki A; Nishie W; Shimizu H
J Dermatol; 2010 Mar; 37(3):194-204. PubMed ID: 20507382
[TBL] [Abstract][Full Text] [Related]
27. Fcγ Receptor IIB Controls Skin Inflammation in an Active Model of Epidermolysis Bullosa Acquisita.
Kovacs B; Tillmann J; Freund LC; Nimmerjahn F; Sadik CD; Bieber K; Ludwig RJ; Karsten CM; Köhl J
Front Immunol; 2019; 10():3012. PubMed ID: 31993051
[TBL] [Abstract][Full Text] [Related]
28. The flavonoid luteolin inhibits Fcγ-dependent respiratory burst in granulocytes, but not skin blistering in a new model of pemphigoid in adult mice.
Oswald E; Sesarman A; Franzke CW; Wölfle U; Bruckner-Tuderman L; Jakob T; Martin SF; Sitaru C
PLoS One; 2012; 7(2):e31066. PubMed ID: 22328927
[TBL] [Abstract][Full Text] [Related]
29. Proteases in Pemphigoid Diseases.
Hiroyasu S; Turner CT; Richardson KC; Granville DJ
Front Immunol; 2019; 10():1454. PubMed ID: 31297118
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic effects of Fc gamma RIV inhibition are mediated by selectively blocking immune complex-induced neutrophil activation in epidermolysis bullosa acquisita.
Haeger SC; Kridin K; Pieper M; Griewahn L; Nimmerjahn F; Zillikens D; König P; Ludwig RJ; Hundt JE
Front Immunol; 2022; 13():938306. PubMed ID: 36311755
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of interferon gamma impairs induction of experimental epidermolysis bullosa acquisita.
Gross N; Marketon J; Mousavi S; Kalies K; Ludwig RJ; Bieber K
Front Immunol; 2024; 15():1343299. PubMed ID: 38799441
[TBL] [Abstract][Full Text] [Related]
32. Monocytes enhance neutrophil-induced blister formation in an ex vivo model of bullous pemphigoid.
de Graauw E; Sitaru C; Horn MP; Borradori L; Yousefi S; Simon D; Simon HU
Allergy; 2018 May; 73(5):1119-1130. PubMed ID: 29222810
[TBL] [Abstract][Full Text] [Related]
33. Myeloid-related proteins-8 and -14 are expressed but dispensable in the pathogenesis of experimental epidermolysis bullosa acquisita and bullous pemphigoid.
Akbarzadeh R; Yu X; Vogl T; Ludwig RJ; Schmidt E; Zillikens D; Petersen F
J Dermatol Sci; 2016 Mar; 81(3):165-72. PubMed ID: 26692467
[TBL] [Abstract][Full Text] [Related]
34. A practical technique for differentiation of subepidermal bullous diseases: localization of in vivo-bound IgG by laser scanning confocal microscopy.
Wozniak K; Kazama T; Kowalewski C
Arch Dermatol; 2003 Aug; 139(8):1007-11. PubMed ID: 12925388
[TBL] [Abstract][Full Text] [Related]
35. Autoimmunity to type VII collagen: epidermolysis bullosa acquisita.
Remington J; Chen M; Burnett J; Woodley DT
Curr Dir Autoimmun; 2008; 10():195-205. PubMed ID: 18460887
[TBL] [Abstract][Full Text] [Related]
36. A case of epidermolysis bullosa acquisita with autoantibody to anti-p200 pemphigoid antigen and exfoliative esophagitis.
Yamada T; Suzuki M; Koike Y; Kida K; Murata S; Ishii N; Hashimoto T; Ohtsuki M
Dermatology; 2006; 212(4):381-4. PubMed ID: 16707891
[TBL] [Abstract][Full Text] [Related]
37. Complement and cutaneous autoimmune blistering diseases.
Lessey E; Li N; Diaz L; Liu Z
Immunol Res; 2008; 41(3):223-32. PubMed ID: 18641925
[TBL] [Abstract][Full Text] [Related]
38. Evidence for pathogenicity of autoreactive T cells in autoimmune bullous diseases shown by animal disease models.
Ujiie H; Shimizu H
Exp Dermatol; 2012 Dec; 21(12):901-5. PubMed ID: 23016514
[TBL] [Abstract][Full Text] [Related]
39. Evidence for a role of eosinophils in blister formation in bullous pemphigoid.
de Graauw E; Sitaru C; Horn M; Borradori L; Yousefi S; Simon HU; Simon D
Allergy; 2017 Jul; 72(7):1105-1113. PubMed ID: 28135772
[TBL] [Abstract][Full Text] [Related]
40. Immune mechanism-targeted treatment of experimental epidermolysis bullosa acquisita.
Ludwig R
Expert Rev Clin Immunol; 2015; 11(12):1365-78. PubMed ID: 26471717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
